drugset / Trial / NCT00702806
Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial was to investigate the appropriate dose of a single injection of Org 36286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF and IVF/ICSI. After seven days, participants were converted to treatment with Puregon® 150 IU and administration of the GnRH antagonist Orgalutran® to finalize the stimulation cycle. Secondary objectives were the safety (including the absence of antibody formation) and the direct effects of Org 36286 on reproductive functions (steroidogenesis, oocyte maturation, embryo quality and implantation).
Timeline
- Start
- 2001-07-01
- Primary completion
- 2002-10-15
- Completion
- 2002-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Corifollitropin alfa | Protein / enzyme biologic | 120 ug | Other |
| Subject | Corifollitropin alfa | Protein / enzyme biologic | 180 ug | Other |
| Subject | Corifollitropin alfa | Protein / enzyme biologic | 240 ug | Other |
| Subject | Follitropin beta | Protein / enzyme biologic | 150 iu | Subcutaneous |
| Background | Ganirelix | Protein / enzyme biologic | 0.25 mg | Subcutaneous |
| Background | human chorionic gonadotropin | Protein / enzyme biologic | 10000 iu | Subcutaneous |